Overview
TriGemX Bio (fka Kallyope) a NYC-based biotechnology company focused on developing a medicines for the treatment of migraine, raised $94M in funding. The round was co-led by The Column Group, TCGX, and Viking Global Investors, with participation from additional investors....See more
Website
https://trigemxbio.com/Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
$94.0M • Funding Round
Announced on 10/1/2026
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.